Our Network of Board-Certified Providers
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
GLP-1 (glucagon-like peptide-1) receptor agonists represent a fundamental shift in how medicine approaches weight management. Unlike traditional approaches that rely solely on willpower, these FDA-approved medications work with your body's own hormonal systems — reducing hunger at the source, slowing digestion, and supporting blood sugar balance. The result? Life-changing, sustained weight loss for patients who have struggled for years. Medications include semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Saxenda).
The clinical trial results speak for themselves: patients lose an average of 15% of body weight with semaglutide and an astonishing 22% with tirzepatide over approximately 72 weeks. Many patients also experience dramatic improvements in blood sugar control, blood pressure, cholesterol, and energy levels — a full-body transformation.[1][2]
Medically reviewed by
Dr. Sarah Mitchell, MD, ABOM
Board-Certified in Obesity Medicine • Last reviewed: June 5, 2026
Your transformation begins with a conversation — online, in the privacy of your home. No waiting rooms, no delays. Connect with a specialist physician who will help you map out your path to lasting change.
Every medication we prescribe — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Saxenda) — has been proven in clinical trials to deliver real, measurable results for real patients.
Your transformation is supported by board-certified physicians who specialize in metabolic health and weight management. They are with you at every milestone — adjusting your plan as you progress toward your goals.
Three landmark randomized controlled trials in the New England Journal of Medicine form the evidence base for FDA-approved GLP-1 weight management medications:
Telehealth prescribing of GLP-1 medications is fully legal in all 50 states when conducted by a properly licensed physician through a HIPAA-compliant platform. GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) are not DEA-scheduled controlled substances — no in-person visit is required by federal or state telehealth law.
Adult obesity rates (CDC Behavioral Risk Factor Surveillance System, 2023) vary significantly across the United States. States with higher obesity prevalence experience the greatest demand for accessible GLP-1 telehealth prescriptions:
Source: CDC Behavioral Risk Factor Surveillance System (BRFSS) 2023. Adult obesity defined as BMI ≥ 30.0.
Select your state to connect with licensed GLP-1 physicians who can help you begin your health transformation — wherever you live.
Patients in the biggest American cities are achieving life-changing results with GLP-1 medications. Find your city and begin your journey.
We have simplified the path to life-changing GLP-1 treatment into three straightforward steps. Your transformation could begin today.
Complete a brief, confidential health questionnaire that covers your weight history, current health conditions, medications, and goals. This information helps your physician understand your full picture and design the most effective GLP-1 treatment for your body.
A board-certified physician reviews your profile and meets with you via secure telehealth. They will present your options, explain what to realistically expect from GLP-1 treatment, and build a customized plan to maximize your results.
Your prescribed GLP-1 medication ships from a licensed US pharmacy directly to your home within 3-5 business days. The moment it arrives, your transformation journey begins — with ongoing physician support at every step.
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Patients using semaglutide (Wegovy) lose an average of 15% of body weight over 68 weeks. Those on tirzepatide (Zepbound) achieve up to 22% average weight reduction over 72 weeks. Beyond the scale, patients typically see improvements in energy levels, blood pressure, blood sugar, cholesterol, sleep quality, and mobility. For many, it is a total body transformation.
Most patients notice reduced appetite and early weight changes within the first 2-4 weeks. Weight loss accelerates as doses increase during the titration phase (typically weeks 4-20). The most dramatic results are typically seen between months 3-6, with continued improvement through the full treatment period.
Clinical research indicates that weight is often regained after discontinuation without lifestyle support. Most physicians recommend pairing GLP-1 therapy with dietary and lifestyle changes to build sustainable habits. Ongoing treatment with dose reduction or maintenance dosing is an option discussed with your physician based on your goals.
GLP-1 medications deliver transformation beyond the scale. Patients experience significant improvements in HbA1c (blood sugar control), systolic blood pressure, triglycerides, and LDL cholesterol. The SELECT cardiovascular trial showed semaglutide reduced major cardiac events by 20% in at-risk patients. GLP-1 is truly a metabolic transformation medication.
GLP-1 medications work through hormonal mechanisms that are distinct from willpower or calorie counting alone. Many patients who have struggled with conventional approaches achieve breakthrough results with GLP-1, because it directly addresses the biological drivers of hunger and metabolic dysfunction that make weight management so difficult.
Black Box Warning: In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and injection site reactions. These typically diminish as dosage is gradually escalated.
Serious side effects may include pancreatitis, gallbladder problems, kidney injury, hypoglycemia (with insulin), and allergic reactions. Consult your healthcare provider immediately if you experience severe symptoms.
Contraindications: History of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy or breastfeeding, severe gastrointestinal disease. This is not a complete list — always discuss your full medical history with your physician.
Clinical References:
